Parkinson's disease (PD) is the second most frequent neurodegenerative brain disease
(NBD) after Alzheimer's disease (AD). Statins are the most common lipid‐lowering agents …

The increasing prevalence of Parkinson disease (PD) highlights the need to develop
interventions aimed at slowing or halting its progression. As a result of sophisticated disease …

Background Statins represent candidates for drug repurposing in Parkinson's disease (PD).
Few studies examined the role of reverse causation, statin subgroups, and dose–response …

The worldwide prevalence of Parkinson's disease (PD) has been constantly increasing in
the last decades. With rising life expectancy, a longer disease duration in PD patients is …

Background The trialed treatment landscape of Parkinson's disease (PD) is extensive, but
up to now, there is no disease-modifying therapy. As the pathophysiology of PD becomes …

Statins are common drugs that are clinically used to reduce elevated plasma cholesterol
levels. Based on their solubility, statins are considered to be either hydrophilic or lipophilic …

Background and Objectives The incidence rate of Parkinson disease (PD) has been
increasing rapidly during the past years. Yet, no treatments exist to prevent or slow the …

Statins have evident neuroprotective role in acute ischemic stroke (AIS). The pleiotropic
effect by which statin exerts neuroprotective effects, needs to be explored for considering it …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of
dopaminergic neurons. While neuronal dysfunction is central to PD, astrocytes also play …

Background Clinical trials of disease‐modifying therapies in PD require valid and
responsive primary outcome measures that are relevant to patients. Objectives The objective …